SPRY vs SVA

ARS Pharmaceuticals, Inc. vs Sinovac Biotech, Ltd. — Valuation Comparison 2026

SPRY

Pharmaceutical Preparations
ARS Pharmaceuticals, Inc.
Quality
4.7
out of 10
Value Trap
24
SAFE
Price
$9.07
Last close
Models
8/13
Active
VS

SVA

Pharmaceutical Preparations
Sinovac Biotech, Ltd.
Quality
2.4
out of 10
Value Trap
Price
$6.47
Last close
Models
5/13
Active

Model-by-Model Comparison

ModelType SPRY Fair ValueSPRY Upside SVA Fair ValueSVA Upside
Bayesian DCF Intrinsic $1.86 -79.5% $29.51 +356.1%
Earnings Power Value Intrinsic $21.15 +227.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.53 -83.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SPRY vs SVA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SPRY vs SVA — Which Stock Is More Undervalued?

SPRY scores higher with a 4.7/10 quality rating vs SVA's 2.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ARS Pharmaceuticals, Inc. (SPRY) and Sinovac Biotech, Ltd. (SVA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SPRY currently trades at $9.07 with a QOC of 4.7/10, while SVA trades at $6.47 with a QOC of 2.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).